Measles Vaccine in HCW

NCT ID: NCT04357028

Last Updated: 2020-12-22

Basic Information

• Recruitment Status: SUSPENDED
• Clinical Phase: PHASE3
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-13
• Study Completion Date: 2021-01-01

Brief Summary

Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV,

The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19.

We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness

Conditions

Covid19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

MMR vaccine

0.5 ml subcutaneous of MMR vaccine will be injected in posterior triceps aspect of upper arm

Group Type: EXPERIMENTAL

Measles-Mumps-Rubella Vaccine

Intervention Type: DRUG

Measles mumps Rubella vaccine is a weak attenuated life vaccine

Control

0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm

Group Type: PLACEBO_COMPARATOR

Placebos

Intervention Type: DRUG

0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm

Interventions

Measles-Mumps-Rubella Vaccine

Measles mumps Rubella vaccine is a weak attenuated life vaccine

Intervention Type: DRUG

Placebos

0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age 18-50 years old
• Subjects who are willing to comply with the requirements of the study protocol and scheduled visits (for example, completion of the subject diary, return for follow-up visits) and who are willing to make themselves available for the duration of the study with access to a consistent means of telephone contact

Exclusion Criteria

• acute severe illness
• recent receipt of a blood product
• history of thrombocytopenia
• Pregnant females
• any chronic medical condition
• Any participant receiving any immune suppressive medication
• Immunocompromised staff
• Participants who have egg allergy
• Participants who care for immune compromised hosts
• Participants who test positive for COVID-19 serology prior to randomization

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Kasr El Aini Hospital

OTHER

Sponsor Role: lead

Responsible Party

Ahmed Mukhtar

professor of anesthesia and intensive care

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Cairo University Hospital

Cairo, , Egypt

Countries

Egypt

Other Identifiers

N-30-2020

Identifier Type: -

Identifier Source: org_study_id